Titan Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Titan Pharmaceuticals
Industry Pharmaceuticals
Headquarters California
Number of employees
14 (Dec 2016)
Website www.titanpharm.com

Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders.

Titan's principal asset is Probuphine,[1][2] a slow-release implant formulation of buprenorphine[3] for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016.[4] It was licensed to Braeburn Pharmaceuticals for marketing and commercialization.[2]


External links[edit]